Bavarian Nordic has entered a drug supply agreement with Bristol-Myers Squibb, under which BMS will supply OPDIVO (nivolumab) for use in a clinical study exploring the benefit of combining CV301 with OPDIVO in patients with previously treated non-small cell lung cancer (NSCLC). OPDIVO is approved for treatment of NSCLC in the second line setting, among other indications.   CV301 targets two tumor-associated antigens, CEA and MUC-1, which are over-expressed in major cancer types, including lung...